



Department of  
**Health**

An Roinn Sláinte

Máinnystrie O Poustie

[www.health-ni.gov.uk](http://www.health-ni.gov.uk)

**For Action:** Assistant Director Integrated Care, Head of Pharmacy and Medicines Management, Strategic Planning and Performance Group & BSO  
Heads of Pharmacy and Medicines Management of HSC Trusts  
Regulation Quality Improvement Authority

From: Chief Pharmaceutical Officer  
Professor Cathy Harrison  
Castle Buildings  
Upper Newtownards Road  
Belfast BT4 3SQ

Telephone: 028 90 523219  
Facsimile: 028 90 522335

E-Mail: [cathy.harrison@health-ni.gov.uk](mailto:cathy.harrison@health-ni.gov.uk)

Our Ref: PHC/13/2024  
Date: 16 April 2024

# M E D I C I N E S R E C A L L

## CLASS 3 MEDICINES RECALL

Action Within 5 Days

Pharmacy/Wholesaler Level Recall

Dear Healthcare Professional,

**A. Menarini Farmaceutica Internazionale Srl**

**Invokana 300mg tablets (Northern Ireland only)**

**PL EU/1/13/884/006**

**SNOMED Code** 24088311000001106

Batch No	Expiry Date	Pack Size	First Distributed
NDL0N00	31/03/2026	30 tablets	8 March 2024

Active Pharmaceutical Ingredient: Canagliflozin hemihydrate

### Brief description of the problem

A. Menarini Farmaceutica Internazionale Srl is recalling the above batch as a precautionary measure due to the distribution of Invokana 300mg in Northern Ireland in packaging intended for the Greek market.

This affects Invokana 300mg (30 tablets) in Northern Ireland only.

**Advice for healthcare professionals**

Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

**Advice for patients**

No further action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

**Further Information**

For medical information enquiries please contact [menarini@medinformation.co.uk](mailto:menarini@medinformation.co.uk).

For stock control enquiries please contact [rmillward@menariniuk.com](mailto:rmillward@menariniuk.com).

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Yours sincerely



Professor Cathy Harrison  
Chief Pharmaceutical Officer